Tue, March 7, 2023

Paul Choi Maintained (BBIO) at Strong Buy with Increased Target to $28 on, Mar 7th, 2023

Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $20 to $28 on, Mar 7th, 2023.

Paul has made no other calls on BBIO in the last 4 months.



There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Paul


  • Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Monday, February 6th, 2023
  • Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $19 on, Monday, January 23rd, 2023